样式: 排序: IF: - GO 导出 标记为已读
-
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-03-12 Michihiro Iwaki, Masato Yoneda, Naohiro Wada, Otani Tomohiro, Takashi Kobayashi, Asako Nogami, Satoru Saito, Nakajima Atsushi
Approved drug therapies for nonalcoholic steatohepatitis (NASH) are lacking, for which various agents are currently being tested in clinical trials. Effective drugs for liver fibrosis, the factor m...
-
An extract of phase II and III trials on recent developments in managing neuropathic pain syndromes: diabetic peripheral neuropathy, trigeminal neuralgia, and postherpetic neuralgia Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-02-27 William C. Upshaw, Lenise G. Soileau, Nicholas R. Storey, Kassady A. Perkinson, Patrick M. Luther, Noah J. Spillers, Christopher L. Robinson, Cole Miller, Shahab Ahmadzadeh, Omar Viswanath, Sahar Shekoohi, Alan D. Kaye
Neuropathic pain (NP) conditions involve lesions to the somatosensory nervous system leading to chronic and debilitating pain. Many patients suffering from NP utilize pharmacological treatments wit...
-
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-02-12 Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, se...
-
Emerging drugs for the treatment of irritability associated with autism spectrum disorder Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-02-04 Ahmad Shamabadi, Hanie Karimi, Razman Arabzadeh Bahri, Mohsen Motavaselian, Shahin Akhondzadeh
Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior ...
-
How will tovorafenib change our treatment of pediatric low-grade glioma? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-02-02 Inci Yaman, Eric Bouffet
Published in Expert Opinion on Emerging Drugs (Vol. 29, No. 1, 2024)
-
Cannabinoid treatment for the symptoms of autism spectrum disorder Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-01-23 Adi Aran, Dalit Cayam Rand
Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 3% of school-age children. The core symptoms are deficits in social communication and restricted and repetiti...
-
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-01-13 Pratheeshaa Nageswaran, Saad Ahmed, Hasan Tahir
GCA (giant cell arteritis) and PMR (polymyalgia rheumatica) are two overlapping inflammatory rheumatic conditions that are seen exclusively in older adults, sharing some common features. GCA is a c...
-
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-01-12 Jordan Beveridge, Eileen Kaniecki, Aniketh Naidu, Bret David Silverglate, George Grossberg
Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-app...
-
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2024-01-11 Panu Wetwittayakhlang, Talat Bessissow, Peter L. Lakatos
Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by unpredictable flare-ups and periods of remission. While several therapeutic options, such as anti-tumor necrosis factor...
-
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Zheng Xian Thng, Albert John Bromeo, S. Saeed Mohammadi, Anadi Khatri, Anh N.T. Tran, Amir Akhavanrezayat, Ngoc T.T. Than, Khiem S. Nguyen, Woong-Sun Yoo, Azadeh Mobasserian, Christopher Chi Mong Or, Quan Dong Nguyen
Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract. It is a leading cause of blindness in developed countries and exerts significant psychologica...
-
Are clinical trials into emerging drugs for the treatment of alpha-1 antitrypsin deficiency providing promising results? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Joshua De Soyza, Anita Pye, Alice M. Turner
Published in Expert Opinion on Emerging Drugs (Vol. 28, No. 4, 2023)
-
Cancer drugs with high repositioning potential for Alzheimer’s disease Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Jad Majeed, Marwan N. Sabbagh, Min H. Kang, J. Josh Lawrence, Kevin Pruitt, Sarah Bacus, Ellie Reyna, Maddy Brown, Boris Decourt
Despite the recent full FDA approval of lecanemab, there is currently no disease modifying therapy (DMT) that can efficiently slow down the progression of Alzheimer’s disease (AD) in the general po...
-
A review of phase II and III drugs for the treatment and management of endometriosis Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Umberto Perrone, Giulio Evangelisti, Antonio Simone Laganà, Stefano Bogliolo, Marcello Ceccaroni, Alberto Izzotti, Claudio Gustavino, Simone Ferrero, Fabio Barra
Endometriosis is an estrogen-dependent disease that gives rise to pelvic pain and infertility. Although estroprogestins and progestins currently stand as the first-line treatments for this conditio...
-
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Carmelo Sofia, Alessia Comes, Giacomo Sgalla, Luca Richeldi
Currently approved drug treatments for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, have been shown to slow lung function decline and improve clinical outcomes. Since significan...
-
New drugs targeting calcitonin gene-related peptide for the management of migraines Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Claudio Tana, Francesco Cipollone, Maria Adele Giamberardino, Paolo Martelletti
Significant advances in migraine research have contributed to the development of new drugs for the treatment of migraine. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP)...
-
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Darosa Lim, Julianne Kleitsch, Victoria P. Werth
Cutaneous lupus erythematosus (CLE) is an autoimmune disease that is clinically heterogenous and may occur with or without the presence of systemic lupus erythematosus (SLE). While existing on a sp...
-
Potential use of psilocybin drugs in the treatment of depression Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Katarzyna Śladowska, Paweł Kawalec, Tomasz Brzostek, Andrzej Pilc
Depression is a common disabling psychiatric disorder, which – in extreme cases – may lead to suicide if untreated or inadequately treated. Despite the availability of various treatments for depres...
-
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-12-26 Andrea Esposito, Paolo Bossi
Published in Expert Opinion on Emerging Drugs (Vol. 28, No. 4, 2023)
-
Apomorphine for Parkinson’s disease: pharmacologic and clinical considerations Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-11-02 Maxwell J Wagner, Charles P Daniel, Connor J Plaisance, Grant E Borne, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye
In Parkinson’s disease, dopamine depletion in the basal ganglia leads to symptoms including bradykinesia, gait abnormalities, and cognitive impairment. Even with treatment, the disease course leads...
-
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-10-31 Seng Kiong Tan, Mark E. Cooper
Published in Expert Opinion on Emerging Drugs (Vol. 28, No. 4, 2023)
-
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-10-12 Giuseppe D’Angelo, Mario Ascione, Ilaria Morra, Paolo Verrazzo, Giuseppe Bifulco, Pierluigi Giampaolino, Luigi Della Corte
Published in Expert Opinion on Emerging Drugs (Vol. 28, No. 3, 2023)
-
A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-10-12 Nikhil Das, Sameer Chaurasia, Rishi P. Singh
Current treatment for age-related macular degeneration poses a large burden on patients and the inability of patients to adhere to this immense burden can lead to worse visual outcomes. Novel treat...
-
Emerging oral drug options for ulcerative colitis Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-09-07 Silvia Salvatori, Benedetto Neri, Irene Marafini, Mattia Brigida, Giovanni Monteleone
Despite the availability of a variety of therapeutic compounds and improved management strategies, one-third of UC patients with moderate-to-severe disease do not benefit from the existing treatmen...
-
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-08-30 Ning Dong, Lucia Perez-Lamas, Julio C Chavez
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell therapy have significantly improved the outco...
-
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-08-08 Magdalena I. Tolea, Reem Ezzeddine, Simone Camacho, James E. Galvin
Despite faster cognitive decline and greater negative impact on patients and family caregivers, drug development efforts in Dementia with Lewy Bodies (DLB) fall behind those for Alzheimer’s Disease...
-
Status of current trials and potential future trials with sparsentan Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-07-23 Howard Trachtman, Radko Komers, Jula Inrig
Published in Expert Opinion on Emerging Drugs (Vol. 28, No. 3, 2023)
-
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-06-23 Flavia Bonini, Luana Guimarães de Sousa, Renata Ferrarotto
ABSTRACT Introduction Cutaneous squamous cell carcinoma (CSCC) is the second most common form of human cancer. Treatment of locally advanced and/or recurrent CSCC is often challenging. A subset of patients are not candidates for curative-intent therapies due to extent of loco-regional disease, refractoriness to prior local therapy, or presence of distant metastasis. Areas covered Traditionally, CSCC
-
Emerging peptide therapeutics for the treatment of ovarian cancer Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-06-07 Ana C. Veneziani, Eduardo Gonzalez-Ochoa, Amit M. Oza
ABSTRACT Introduction The discovery of therapeutic proteomic targets has resulted in remarkable advances in oncology. Identification of functional and hallmark peptides in ovarian cancer can be leveraged for diagnostic and therapeutic targeting. These targets are expressed in different tumor cell locations, making them excellent candidates for theranostic imaging, precision therapeutics, and immunotherapy
-
Systemic mastocytosis: 2023 update on diagnosis and management in adults Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-06-06 Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Claudia Ielo, Chiara Masucci, Mauro Passucci, Maurizio Martelli, Massimo Breccia
Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. In 2022 both the World Health Organization (WHO) and...
-
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-05-09 Francesca Casaluce, Cesare Gridelli
ABSTRACT Introduction Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) as the most common subtype. In the past decades, immunotherapy deeply changed paradigms for care of newly diagnosed advanced NSCLC patients without oncogenic driver mutations. An immunotherapy-based regimen alone or in combination to chemotherapy was crowned as the preferred
-
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-05-08 Robert I. Fox, Carla M. Fox, Sara S. McCoy
ABSTRACT Introduction Sjögren’s Disease, SjD, is a systemic autoimmune disorder characterized by reduced function of the salivary and lacrimal glands. Patients suffer from dryness, fatigue, and pain and may present with or without extra-glandular organ involvement. Symptoms limit SjD patients’ quality of life and are the most difficult to improve with therapy. SjD patients are heterogeneous and clustering
-
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-04-28 Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, Francesca Trojsi, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo
ABSTRACT Introduction Migraine is a leading cause of years lived with disability and preventive strategies represent a mainstay to reduce health-related disability and improve quality of life of migraine patients. Until a few years ago, migraine prevention was based on drugs developed for other clinical indications and relocated in the migraine therapeutic armamentarium, characterized by unfavorable
-
Emerging drugs for hepatitis D Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-04-27 Onur Keskin, Cihan Yurdaydin
ABSTRACT Introduction Chronic hepatitis delta (CHD) is the most severe form of chronic viral hepatitis. Until recently, its treatment consisted of pegylated interferon alfa (pegIFN) use. Areas covered Current and new drugs for treating CHD. Virus entry inhibitor bulevirtide has received conditional approval by the European Medicines Agency. Prenylation inhibitor lonafarnib and pegIFN lambda are in
-
Emerging drugs in the treatment of chronic cough Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-04-24 Danica Brister, Mustafaa Wahab, Moaaz Rashad, Nermin Diab, Martin Kolb, Imran Satia
ABSTRACT Introduction Chronic cough is a debilitating condition that is among the most common reasons for seeking medical attention yet remains challenging to manage. Identifying an underlying respiratory, nasal, or upper gastrointestinal disease triggering cough is the first step in assessment, but once this has been ruled out or adequately treated, many patients remain troubled with chronic cough
-
A review of emerging factor XI inhibitors Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-03-21 Sandra Elsheikh, Nicola Tidbury, Gregory Y.H. Lip
ABSTRACT Introduction Whilst the introduction of direct oral anticoagulants (DOACs) has improved the prevention of thromboembolic events, there is still a need for safer anticoagulants. This is particularly so, for specific populations of patients, such as those with an increased bleeding risk or those with severely reduced kidney function. People with Factor XI (FXI) deficiency are at reduced risk
-
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-03-20 Thinzar Min, Stephen C Bain
ABSTRACT Introduction Despite therapeutic advances in the field of diabetes management since the discovery of insulin 100 years ago, there are still unmet clinical needs for people with type 1 diabetes mellitus (T1DM). Areas covered Genetic testing and islet autoantibodies testing allow researchers to design prevention studies. This review discusses the emerging therapy for prevention of T1DM, disease
-
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-03-07 Rohit K Jain, Avani M Singh, Xuefeng Wang, José A. Guevara-Patiño, Guru Sonpavde
ABSTRACT Introduction The treatment landscape for advanced-stage, unresectable or metastatic urothelial carcinoma (mUC) has shifted dramatically over a short period of time, with new therapeutic agents available for clinical use. However, despite these recent advances in the field, mUC continues to be a disease with significant morbidity and mortality and remains generally incurable. While platinum-based
-
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2023-03-07 Laura Neurath, Ferdinando D’Amico, Silvio Danese
ABSTRACT Introduction Current therapeutic options for patients with ulcerative colitis comprise monoclonal antibodies against tumor necrosis factor (TNF), alpha4/beta7 integrin, and interleukin (IL)12/23 as well as small molecules such as tofacitinib, upadacitinib, ozanimod, and filgotinib. However, many patients fail to respond to these agents or have loss of response over time. Therefore, there is
-
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’ Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-12-23 Anastasios Georgiadis, Alexander J. Smith, Michel Michaelides, Stuart Naylor, Alexandria Forbes
Published in Expert Opinion on Emerging Drugs (Vol. 27, No. 4, 2022)
-
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-12-23 Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E. MacLaren
ABSTRACT Introduction Mutations in the RPGR gene are responsible for one of the most prevalent and severe types of retinitis pigmentosa. Gene therapy has shown great promise to treat inherited retinal diseases, and currently, four RPGR gene therapy vectors are being evaluated in clinical trials. Areas covered This manuscript reviews the gene therapy products that are in development for X-linked retinitis
-
Response: ‘letter to the editor: emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’ Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-12-23 Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic, Robert E. MacLaren
Published in Expert Opinion on Emerging Drugs (Vol. 27, No. 4, 2022)
-
Emerging drugs for the treatment of diabetic nephropathy Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-12-09 Yoon Kook Kim, Xinyuan Ning, Kashif M. Munir, Stephen N. Davis
ABSTRACT Introduction Diabetic nephropathy remains a significant economic and social burden on both the individual patient and health-care systems as the prevalence of diabetes increases in the general population. The complex pathophysiology of diabetic kidney disease poses a challenge in the development of effective medical treatments for the disease. However, the multiple facets of diabetic nephropathy
-
Emerging antiviral therapies and drugs for the treatment of influenza Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-11-24 Jinshen Wang, Yihang Sun, Shuwen Liu
ABSTRACT Introduction Both vaccines and antiviral drugs represent the mainstay for preventing and treating influenza. However, approved M2 ion channel inhibitors, neuraminidase inhibitors, polymerase inhibitors, and various vaccines cannot meet therapeutic needs because of viral resistance. Thus, the discovery of new targets for the virus or host and the development of more effective inhibitors are
-
Emerging drugs for the treatment of alopecia areata Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-11-21 Hassiel Aurelio Ramírez-Marín, Antonella Tosti
ABSTRACT Introduction Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent
-
Emerging drugs for the treatment of inflammatory bowel disease Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-11-17 Uni Wong, Raymond K Cross
ABSTRACT Introduction Anti-tumor necrosis factor (TNF)-α have been the mainstay therapy for Crohn’s (CD) and ulcerative colitis (UC) for decades. With growing need for highly effective therapy, various therapeutic targets have been introduced including anti-integrins, anti-interleukin (IL) 12/23, selective anti-IL23, Janus Kinase (JAK) inhibitors, sphingosine-1-phosphate (S1P) receptor modulators,
-
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-11-11 David De Bels, Evelyne Maillart, Françoise Van Bambeke, Sebastien Redant, Patrick M. Honoré
ABSTRACT Introduction Invasive candidiasis or candidemia is a severe infection affecting more than 250,000 people worldwide every year. It is present in up to 16% of ICU patients. The prognosis of these infections is unfavorable, with global death estimated around 50,000 per year, which corresponds to up to 40% depending on patient severity and comorbidities. Therapeutic failure is not rare due to
-
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-11-03 Udo Rudloff
ABSTRACT Introduction Pancreatic cancer is one of the deadliest solid organ cancers. In the absence of specific warning symptoms pancreatic cancer is diagnosed notoriously late. Current systemic chemotherapy regimens extend survival by a mere few months. With the advances in genetic, proteomic, and immunological profiling there is strong rationale to test kinase inhibitors to improve outcome. Areas
-
Is clinical trial data showing positive progress for the treatment of eosinophilic esophagitis? Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-10-18 Robert D. Pesek, Sandeep K. Gupta
Published in Expert Opinion on Emerging Drugs (Vol. 27, No. 3, 2022)
-
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-10-06 Helena Bote, Andrés Mesas, Javier Baena, Mercedes Herrera, Luis Paz-Ares
ABSTRACT Introduction Over the last decade, immune checkpoint inhibitors (ICIs) have impacted on the standard therapy for patients with non-small cell lung cancer (NSCLC). ICIs first showed efficacy in patients with advanced disease who had progressed after chemotherapy, later reaching the first-line therapy context alone, in combination with chemotherapy, and/or with dual-immunotherapy regimens. Areas
-
Emerging injectable therapies for osteoarthritis Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-10-03 Julia Sewell, Andrew Östör
ABSTRACT Osteoarthritis (OA) affects more than 240 million people worldwide. In 2016, the Osteoarthritis Research Society International submitted a report to the United States Food and Drug Administration highlighting OA as a ‘serious’ disease, and appealed for the urgent development and review of new therapies to address a significant unmet need. Despite this, international guidelines for the treatment
-
Emerging tyrosine kinase inhibitors for head and neck cancer Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-09-21 Zhen Long, Jennifer R. Grandis, Daniel E. Johnson
ABSTRACT Introduction Conventional regimens for head and neck squamous cell carcinoma (HNSCC) are limited in efficacy and are associated with adverse toxicities. Food and Drug Administration (FDA) approved molecular targeting agents include the HER1 (EGFR)-directed monoclonal antibody cetuximab and the immune checkpoint inhibitors nivolumab and pembrolizumab. However, clinical benefit is only seen
-
Emerging drugs for the treatment of major depressive disorder Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-09-20 Jennifer Hong, Darian Vernon, Jelena Kunovac, Stephen Stahl
ABSTRACT Introduction Major depressive disorder (MDD) continues to be one of the highest contributors to disease burden and years lived with disability in the world. Current existing treatments have been associated with intolerable side effects, long onset of action and suboptimal remission rates. Newer agents are being developed that will be reviewed here, such as glutamate and gamma-aminobutyric
-
Emerging hormonal agents for the treatment of prostate cancer Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-09-09 Emily Bochner, Sam Gold, Ganesh V. Raj
ABSTRACT Introduction Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal alternatives. The landscape of prostate cancer treatment has transformed and taken shape over the last 20 years with novel hormonal and non-hormonal therapeutics that
-
Correction Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-08-21
Published in Expert Opinion on Emerging Drugs (Vol. 27, No. 3, 2022)
-
Emerging drugs for the treatment of bladder storage dysfunction Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-08-18 Karl-Erik Andersson
ABSTRACT Introduction Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still
-
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-08-12 Tyler M. Kaplan, Arthur J. Sit
ABSTRACT Introduction Glaucoma is a progressive optic neuropathy and the leading cause of irreversible vision loss. By 2040, the number of individuals with glaucoma is expected to nearly double. The only known modifiable risk factor for glaucoma is intraocular pressure. Topical medications are often used as first-line therapies. Although there are numerous available treatments, there continues to be
-
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-08-10 Siddharth Bhatt, Rohit Kothari, Durga Madhab Tripathy, Sunmeet Sandhu, Mahsa Babaei, Mohamad Goldust
ABSTRACT Introduction Acne vulgaris is one of the commonest dermatoses encountered in a dermatology clinic. Although the inflammatory processes are centered around the pilosebaceous unit, a myriad of external factors that alter the pathogenesis have been hypothesized. Newer therapies are focused on targeting these as possible scaffolds for drug development. Existing topical and oral medications have
-
Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-08-01 Jules M. Ross, Stéphanie Forté, Denis Soulières
ABSTRACT Introduction The substitution of glutamic acid by valine on the ß-globin chain produces the hemoglobin S variant responsible for sickle cell disease (SCD), a disorder that affects millions of people worldwide and leads to acute and cumulative organ damage. Even though life expectancy has significantly improved where the best medical care is available, there are still few therapeutic options
-
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-07-28 Denise Battaglini, Chiara Robba, Paolo Pelosi, Patricia R.M. Rocco
ABSTRACT Introduction Ventilatory management and general supportive care of acute respiratory distress syndrome (ARDS) in the adult population have led to significant clinical improvements, but morbidity and mortality remain high. Pharmacologic strategies acting on the coagulation cascade, inflammation, oxidative stress, and endothelial cell injury have been targeted in the last decade for patients
-
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency Expert Opin. Emerg. Drugs (IF 3.4) Pub Date : 2022-07-26 Andrea Zanichelli, Vincenzo Montinaro, Massimo Triggiani, Francesco Arcoleo, Debora Visigalli, Mauro Cancian
ABSTRACT Introduction Hereditary angioedema due to C1-inhibitor (C1-INH-HAE) is a rare disease characterized by unpredictable swelling attacks that may be life-threatening when affecting the upper airways. Understanding the pathophysiology of HAE and the mechanism of bradykinin-mediated angioedema allowed the development of new therapies for the treatment of HAE: clinical trials are ongoing to expand